ArticleJournal of global health2023
The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040.
Article in Journal of global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Comparison of the efficacy of different orthotopic neobladder reconstruction techniques following radical cystectomy for bladder cancer: a network meta-analysis.Frontiers in oncology · 2026Pooled it
- Effects of self-management interventions on self-care ability and quality of life in patients with urinary ostomy after bladder cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- A meta-analytic appraisal of robotic-assisted cystectomy outcomes in the elderly octogenarian population.Journal of robotic surgery · 2025Pooled it
- Prognostic value of the systemic immune-inflammation index in bladder cancer: an update evidence-based analysis.Frontiers in oncology · 2025Pooled it
- Psychological Distress in Bladder Cancer Patients: A Systematic Review.Cancer medicine · 2024Pooled it
- Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.International journal of clinical oncology · 2026Trial
- Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.Future science OA · 2026Review
- A synergistic cascade nanoreactor breaks bladder cancer chemoresistance: Synergizing cholesterol metabolism reprogramming with cGAS-STING-mediated metallotherapy.Materials today. Bio · 2026Article
- Development and internal validation of a clinical nomogram for predicting major postoperative pulmonary complications following radical cystectomy: a retrospective cohort study.Translational andrology and urology · 2026Article
- Review
- Deep Learning-Assisted Accuracy Improvement in Bladder Cancer Staging of Spectrum-Aided Visual Enhanced Cystoscopy Images.Biosensors · 2026Article
- Article
- Circ_0001495 promotes bladder cancer progression by regulating miR-1184 via MAPK signaling pathway.Molecular biology reports · 2026Article
- Aspirin or non-steroidal anti-inflammatory drug initiation and subsequent bladder cancer evaluation.Journal of internal medicine · 2026Article
- Holmium laser en‑bloc vs bipolar and conventional monopolar TURBT for non‑muscle‑ınvasive bladder cancer.International urology and nephrology · 2026Article
- Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.Infectious diseases of poverty · 2026Article
- Rural-urban disparities in high‑risk non-muscle‑invasive bladder cancer: lessons from the Canadian Bladder Cancer Information System.Translational andrology and urology · 2026Article
- Structural Misalignment Between Regulatory Definitions of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer and Real-World Clinical Practice.Healthcare (Basel, Switzerland) · 2026Article
- Matricellular Proteins in Bladder Cancer: Context-Dependent Roles in Tumor Promotion and Suppression.International journal of molecular sciences · 2026Review
- Multi-DECT image-based intra- and peritumoral interpretable radiomics and artificial intelligence models for preoperative prediction of pathological grading of non-muscle-invasive bladder cancer.Abdominal radiology (New York) · 2026Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Bladder cancer (BCa) is one of the most common urological malignancies worldwide. This study examines the global epidemiological profile of BCa incidence and mortality in 2020 and the projected burden to 2040. Methods: The estimated number of BCa cases and deaths were extracted from the GLOBOCAN 2020 database. Age-standardised incidence rates (ASIRs) and age-standardised mortality rates (ASMRs) were calculated using the world standard. The predicted BCa incidence and mortality in 2040 was calculated based on demographic projections. Results: Globally, approximately 573 000 new BCa cases and 213 000 deaths occurred in 2020, corresponding to ASIRs and ASMRs of 5.6 and 1.9 per 100 000, respectively. The incidence and mortality rates were approximately 4-fold higher in men (9.5 and 3.3 per 100 000, respectively) than women (2.4 and 0.9, respectively). Across world regions, incidence rates varied at least 12-fold among men and 8-fold among women, with the highest ASIRs for both men and women detected in Southern Europe (26.5 and 5.8 per 100 000, respectively) and Western Europe (21.5 and 5.8, respectively) and the lowest in Middle Africa (2.2) in men and South-Central Asia (0.7) in women. The highest ASMRs for both men and women were found in Northern Africa (9.2 and 1.8 per 100 000, respectively). By 2040, the annual number of new BCa cases and deaths will increase to 991 000 (72.8% increase from 2020) and 397 000 (86.6% increase), respectively. Conclusions: Geographical distributions of BCa incidence and mortality uncovered higher risk of BCa incidence in Southern and Western European populations and higher risk of mortality in Northern African populations. Considering the predicted 73% and 87% increase in annual BCa cases and deaths by 2040 globally, respectively, there is an urgent need to develop and accelerate BCa control initiatives for high-risk populations to tackle global BCa burden and narrow its geographical disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.